In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional bene... by Michal Geva, Ralf Reilmann, Robin Schubert, Kelly Chen, Y Paul Goldberg, Michael R. Hayden

Get full text

The phase 3 PROOF-HD trial demonstrates persistent benefits of pridopidine on function, cognition, and motor function through the 6 month open label extension in Huntington disease... by Michal Geva, Ralf Reilmann, Andrew Feigin, Anne Rosser, Sandra Kostyk, Kelly Chen, Yael Cohen, Y Paul Goldberg, Michael R. Hayden

Get full text

Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial by Michal Geva, Y Paul Goldberg, Melanie L. Leitner, Kelly Chen, Wei Feng, Noga Gershoni Emek, James D. Berry, Sabrina Paganoni, Jeremy Shefner, Merit ECudkowicz, Michael R. Hayden

Get full text

Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target by L. Llaó-Cid, JKL Wong, I. Fernandez Botana, Y. Paul, M. Wierz, L-M Pilger, A. Floerchinger, CL Tan, S. Gonder, G. Pagano, M. Chazotte, K. Bestak, C. Schifflers, M. Iskar, T. Roider, F. Czernilofsky, P-M Bruch, JP Mallm, A. Cosma, DE Campton, E. Gerhard-Hartmann, A. Rosenwald, D. Colomer, E. Campo, D. Schapiro, EW Green, S. Dietrich, P. Lichter, E. Moussay, J. Paggetti, M. Zapatka, M. Seiffert

Get full text